Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL

Vascular Pharmacology

Volumn 82, Issue , 2016, Pages 30-40

  Harper, Emma ^a   Forde, Hannah ^a,b   Davenport, Colin ^b   Rochfort, Keith D ^c   Smith, Diarmuid ^b   Cummins, Philip M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

OPG; RANKL; TRAIL; Type 2 diabetes mellitus; Vascular calcification

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CARDIOVASCULAR AGENT; TNFRSF11B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPLICATION; DIABETIC ANGIOPATHIES; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PLAQUE, ATHEROSCLEROTIC; RANK LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR CALCIFICATION;

EID: 84984644925     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.02.003     Document Type: Review

References (138)

1. [1] Rubin, M.R., Silverberg, S.J., Vascular calcification and osteoporosis — the nature of the nexus. J Clin Endocrinol Metab 89 (2004), 4243–4245.
2. [2] Demer, L.L., Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation. Circulation 83 (1991), 2083–2093.
3. [3] Proudfoot, D., Shanahan, C.M., Biology of calcification in vascular cells: intima versus media. Herz 26 (2001), 245–251.
4. [4] Lehto, S., Niskanen, L., Suhonen, M., Ronnemaa, T., Laakso, M., Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16 (1996), 978–983.
5. [5] Trouvin, A.P., Goëb, V., Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5 (2010), 345–354.
6. [6] Ducy, P., Schinke, T., Karsenty, G., The osteoblast: a sophisticated fibroblast under central surveillance. Science 289 (2000), 1501–1504.
7. [7] Teitelbaum, S.L., Bone resorption by osteoclasts. Science 289 (2000), 1504–1508.
8. [8] Kearns, A.E., Khosla, S., Kostenuik, P.J., Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29 (2008), 155–192.
9. [9] Boyce, B.F., Xing, L., Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther, 9, 2007, S1.
10. [10] Wada, T., Nakashima, T., Hiroshi, N., Penninger, J.M., RANKL–RANK signalling in osteoclastogenesis and bone disease. Trends Mol Med 12 (2006), 17–25.
11. [11] Myers, D.E., Collier, F.M., Minkin, C., Wang, H., Holloway, W.R., Malakellis, M., et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 463 (1999), 295–300.
12. [12] Atkins, G.J., Kostakis, P., Vincent, C., Farrugia, A.N., Houchins, J.P., Findlay, D.M., et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 21 (2006), 1339–1349.
13. [13] Luan, X., Lu, Q., Jiang, Y., Zhang, S., Wang, Q., Yuan, H., et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 189 (2012), 245–252.
14. [14] Liu, C., Walter, T.S., Huang, P., Zhang, S., Zhu, X., Wu, Y., et al. Structural and functional insights of RANKL–RANK interaction and signaling. J Immunol 184 (2010), 6910–6919.
15. [15] Ikeda, T., Kasai, M., Utsuyama, M., Hirokawa, K., Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142 (2001), 1419–1426.
16. [16] Lacey, D.L., Boyle, W.J., Simonet, W.S., Kostenuik, P.J., Dougall, W.C., Sullivan, J.K., et al. Bench to bedside: elucidation of the OPG-RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11 (2012), 401–419.
17. [17] Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-Hora, M., Feng, J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17 (2011), 1231–1234.
18. [18] Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999), 315–323.
19. [19] Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998), 165–176.
20. [20] Hofbauer, L.C., Schoppet, M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004), 490–495.
21. [21] Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.I., Yano, K., Fujise, N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998), 1329–1337.
22. [22] Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273 (1998), 5117–5123.
23. [23] Venuraju, S.M., Yerramasu, A., Corder, R., Lahiri, A., Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55 (2010), 2049–2061.
24. [24] Demer, L.L., Cholesterol in vascular and valvular calcification. Circulation 104 (2001), 1881–1883.
25. [25] Orimo, H., The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 77 (2010), 4–12.
26. [26] Singh, D.K., Winocour, P., Summerhayes, B., Kaniyur, S., Viljoen, A., Sivakumar, G., et al. Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function. Diabetes Res Clin Pract 97 (2012), 158–165.
27. [27] Panizo, S., Cardus, A., Encinas, M., Parisi, E., Valcheva, P., López-Ongil, S., et al. RANKL increases vascular smooth muscle cell calcification through a RANK–BMP4-dependent pathway. Circ Res 104 (2009), 1041–1048.
28. [28] Ross, R., Atherosclerosis — an inflammatory disease. N Engl J Med 340 (1999), 115–126.
29. [29] Cunningham, K.S., Gotlieb, A.I., The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 85 (2005), 9–23.
30. [30] Aronson, D., Rayfield, E.J., How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol, 1, 2002, 1.
31. [31] Singh, D.K., Winocour, P., Summerhayes, B., Viljoen, A., Sivakumar, G., Farrington, K., Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?. Diabetes Res Clin Pract 85 (2009), 258–264.
32. [32] Singh, D.K., Winocour, P., Farrington, K., Review: endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes. Br J Diab Vasc Dis Res 10 (2010), 71–77.
33. [33] Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997), 78–81.
34. [34] Speer, M.Y., Yang, H.Y., Brabb, T., Leaf, E., Look, A., Lin, W.L., et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 104 (2009), 733–741.
35. [35] Steitz, S.A., Speer, M.Y., Curinga, G., Yang, H.Y., Haynes, P., Aebersold, R., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89 (2001), 1147–1154.
36. [36] Tintut, Y., Demer, L., Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Invest Med 54 (2006), 395–401.
37. [37] Papadopouli, A.E., Klonaris, C.N., Theocharis, S.E., Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol 23 (2008), 497–506.
38. [38] Yamaguchi, A., Akashi, T., Vascular calcification: mutual interaction between bone and blood vessel. Clin Calcium 20 (2010), 1669–1676.
39. [39] Bessueille, L., Fakhry, M., Hamade, E., Badran, B., Magne, D., Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: a possible role for IL-1β. FEBS Lett 589 (2015), 2797–2804.
40. [40] Sage, A.P., Tintut, Y., Demer, L.L., Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 7 (2010), 528–536.
41. [41] Ndip, A., Williams, A., Jude, E.B., Serracino-Inglott, F., Richardson, S., Smyth, J.V., et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 60 (2011), 2187–2196.
42. [42] Kaden, J.J., Bickelhaupt, S., Grobholz, R., Haase, K.K., Sarikoç, A., Kiliç, R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004), 57–66.
43. [43] Collin-Osdoby, P., Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95 (2004), 1046–1057.
44. [44] Schoppet, M., Al-Fakhri, N., Franke, F.E., Katz, N., Barth, P.J., Maisch, B., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 (2004), 4104–4112.
45. [45] Gochuico, B.R., Zhang, J., Ma, B.Y., Marshak-Rothstein, A., Fine, A., TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 278 (2000), L1045–L1050.
46. [46] Sato, K., Niessner, A., Kopecky, S.L., Frye, R.L., Goronzy, J.J., Weyand, C.M., TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203 (2006), 239–250.
47. [47] Emery, J.G., McDonnell, P., Burke, M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998), 14363–14367.
48. [48] Li, J.H., Kirkiles-Smith, N.C., McNiff, J.M., Pober, J.S., TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171 (2003), 1526–1533.
49. [49] Kavurma, M.M., Schoppet, M., Bobryshev, Y.V., Khachigian, L.M., Bennett, M.R., TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 283 (2008), 7754–7762.
50. [50] Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003), 2250–2256.
51. [51] Secchiero, P., Zerbinati, C., Rimondi, E., Corallini, F., Milani, D., Grill, V., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61 (2004), 1965–1974.
52. [52] Vitovski, S., Phillips, J.S., Sayers, J., Croucher, P.I., Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282 (2007), 31601–31609.
53. [53] Di Bartolo, B.A., Schoppet, M., Mattar, M.Z., Rachner, T.D., Shanahan, C.M., Kavurma, M.M., Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 91 (2011), 537–545.
54. [54] Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., Secchiero, P., TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104 (2004), 2044–2050.
55. [55] Di Bartolo, B.A., Cartland, S.P., Harith, H.H., Bobryshev, Y.V., Schoppet, M., Kavurma, M.M., TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One, 8, 2013, e74211.
56. [56] Olesen, M., Skov, V., Mechta, M., Mumm, B.H., Rasmussen, L.M., No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol 362 (2012), 149–156.
57. [57] Byon, C.H., Sun, Y., Chen, J., Yuan, K., Mao, X., Heath, J.M., et al. Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 31 (2011), 1387–1396.
58. [58] Chasseraud, M., Liabeuf, S., Mozar, A., Mentaverri, R., Brazier, M., Massy, Z.A., et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Ther Apher Dial 15 (2011), 140–146.
59. [59] Corallini, F., Gonelli, A., D'Aurizio, F., di Iasio, M.G., Vaccarezza, M., Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. Eur J Histochem 53 (2009), 19–24.
60. [60] Eddahibi, S., Guignabert, C., Barlier-Mur, A.M., Dewachter, L., Fadel, E., Dartevelle, P., et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113 (2006), 1857–1864.
61. [61] Chiu, J.J., Usami, S., Chien, S., Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann Med 41 (2009), 19–28.
62. [62] Osako, M.K., Nakagami, H., Koibuchi, N., Shimizu, H., Nakagami, F., Koriyama, H., et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 107 (2010), 466–475.
63. [63] Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998), 1260–1268.
64. [64] Callegari, A., Coons, M.L., Ricks, J.L., Yang, H.L., Gross, T.S., Huber, P., et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 33 (2013), 2491–2500.
65. [65] Callegari, A., Coons, M.L., Ricks, J.L., Rosenfeld, M.E., Scatena, M., Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-κB ligand and interleukin 6. J Vasc Res 51 (2014), 118–131.
66. [66] Secchiero, P., Corallini, F., Pandolfi, A., Consoli, A., Candido, R., Fabris, B., et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169 (2006), 2236–2244.
67. [67] Secchiero, P., Candido, R., Corallini, F., Zacchigna, S., Toffoli, B., Rimondi, E., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114 (2006), 1522–1530.
68. − mice. Diabetologica 54 (2011), 3157–3167.
69. [69] Zauli, G., Rimondi, E., Stea, S., Baruffaldi, F., Stebel, M., Zerbinati, C., et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214 (2008), 117–125.
70. [70] Budoff, M.J., Hokanson, J.E., Nasir, K., Shaw, L.J., Kinney, G.L., Chow, D., et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 3 (2010), 1229–1236.
71. [71] Detrano, R., Guerci, A.D., Carr, J.J., Bild, D.E., Burke, G., Folsom, A.R., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358 (2008), 1336–1345.
72. [72] Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologica 44 (2001), S14–S21.
73. [73] Shao, J.S., Cheng, S.L., Sadhu, J., Towler, D.A., Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55 (2010), 579–592.
74. [74] Van Campenhout, A., Golledge, J., Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204 (2009), 321–329.
75. [75] Di Bartolo, B.A., Kavurma, M.M., Regulation and function of Rankl in arterial calcification. Curr Pharm Des 20 (2014), 5853–5861.
76. [76] Reinhard, H., Lajer, M., Gall, M.A., Tarnow, L., Parving, H.H., Rasmussen, L.M., et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 33 (2010), 2561–2566.
77. [77] Vik, A., Mathiesen, E.B., Brox, J., Wilsgaard, T., Njølstad, I., Jørgensen, L., et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost 9 (2011), 638–644.
78. [78] O'Sullivan, E.P., Ashley, D.T., Davenport, C., Devlin, N., Crowley, R., Agha, A., et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev 26 (2010), 496–502.
79. [79] Abedin, M., Omland, T., Ueland, T., Khera, A., Aukrust, P., Murphy, S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 99 (2007), 513–518.
80. [80] Schoppet, M., Sattler, A.M., Schaefer, J.R., Herzum, M., Maisch, B., Hofbauer, L.C., Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 (2003), 1024–1028.
81. [81] Ziegler, S., Kudlacek, S., Luger, A., Minar, E., Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 (2005), 175–180.
82. [82] Omland, T., Ueland, T., Jansson, A.M., Persson, A., Karlsson, T., Smith, C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008), 627–633.
83. [83] Higgins, C.L., Isbilir, S., Basto, P., Chen, I.Y., Vaduganathan, M., Vaduganathan, P., et al. Distribution of alkaline phosphatase, osteopontin, rank ligand and osteoprotegerin in calcified human carotid atheroma. Protein J 34 (2015), 315–328.
84. [84] Morony, S., Tintut, Y., Zhang, Z., Cattley, R.C., Van, G., Dwyer, D., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation 117 (2008), 411–420.
85. [85] Jung, C.H., Lee, W.Y., Kim, S.Y., Jung, J.H., Rhee, E.J., Park, C.Y., et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 47 (2010), 145–152.
86. [86] Gaudio, A., Privitera, F., Pulvirenti, I., Canzonieri, E., Rapisarda, R., Fiore, C.E., Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand and serum levels and carotid intima–media thickness in patients with type 2 diabetes mellitus. Panminerva Med 56 (2014), 221–225.
87. [87] Rozas Moreno, P., Reyes García, R., García-Martín, A., Varsavsky, M., García-Salcedo, J.A., Muñoz-Torres, M., Serum osteoprotegerin: bone or cardiovascular marker in type 2 diabetes males?. J Endocrinol Invest 36 (2013), 16–20.
88. [88] Poulsen, M.K., Nybo, M., Dahl, J., Hosbond, S., Poulsen, T.S., Johansen, A., et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol, 10, 2011, 76.
89. [89] Tavintharan, S., Pek, L.T., Liu, J.J., Ng, X.W., Yeoh, L.Y., Su Chi, L., et al. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus. Diab Vasc Dis Res 11 (2014), 359–362.
90. [90] Anand, D.V., Lahiri, A., Lim, E., Hopkins, D., Corder, R., The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47 (2006), 1850–1857.
91. [91] Anand, D.V., Lim, E., Darko, D., Bassett, P., Hopkins, D., Lipkin, D., et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 50 (2007), 2218–2225.
92. [92] Giaginis, C., Papadopouli, A., Zira, A., Katsargyris, A., Klonaris, C., Theocharis, S., Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 18 (2012), CR597–CR604.
93. [93] Poornima, I.G., Mackey, R.H., Buhari, A.M., Cauley, J.A., Matthews, K.A., Kuller, L.H., Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women. Menopause 21 (2014), 702–710.
94. [94] Loncar, G., Bozic, B., Cvorovic, V., Radojicic, Z., Dimkovic, S., Markovic, N., et al. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 37 (2010), 148–156.
95. [95] Mohammadpour, A.H., Shamsara, J., Nazemi, S., Ghadirzadeh, S., Shahsavand, S., Ramezani, M., Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: a pilot study. Thrombosis, 2012, 10.1155/2012/306263 ([Epub ahead of print]).
96. [96] Secchiero, P., Corallini, F., Ceconi, C., Parrinello, G., Volpato, S., Ferrari, R., et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One, 4, 2009, e4442.
97. [97] Niessner, A., Hohensinner, P.J., Rychli, K., Neuhold, S., Zorn, G., Richter, B., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30 (2009), 789–796.
98. [98] Mori, K., Ikari, Y., Jono, S., Shioi, A., Ishimura, E., Emoto, M., et al. Association of serum TRAIL level with coronary artery disease. Thromb Res 125 (2010), 322–325.
99. [99] Volpato, S., Ferrucci, L., Secchiero, P., Corallini, F., Zuliani, G., Fellin, R., et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 215 (2011), 452–458.
100. [100] Kawano, N., Mori, K., Emoto, M., Lee, E., Kobayashi, I., Yamazaki, Y., et al. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 91 (2011), 316–320.
101. [101] Galeone, A., Brunetti, G., Oranger, A., Greco, G., Di Benedetto, A., Mori, G., et al. Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol 169 (2013), 296–304.
102. [102] Wu, M., Rementer, C., Giachelli, C.M., Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93 (2013), 365–373.
103. [103] Bolon, B., Campagnuolo, G., Feige, U., Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci 59 (2002), 1569–1576.
104. [104] Fernández-González, F.J., Cañigral, A2., López-Caballo, J.L., Brizuela, A., Cobo, T., de Carlos, F., et al. Recombinant osteoprotegerin effects during orthodontic movement in a rat model. Eur J Orthod, 2015 (pii: cjv056 [Epub ahead of print]).
105. [105] Yao, Y., Wang, G., Wang, Z., Wang, C., Zhang, H., Liu, C., Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. J Oral Maxillofac Surg 69 (2011), e446–e455.
106. [106] Miyazaki, T., Tokimura, F., Tanaka, S., A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence 8 (2014), 463–471.
107. [107] Suresh, E., Abrahamsen, B., Denosumab: a novel antiresorptive drug for osteoporosis. Cleve Clin J Med 82 (2015), 105–114.
108. [108] Kostenuik, P.J., Nguyen, H.Q., McCabe, J., Warmington, K.S., Kurahara, C., Sun, N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24 (2009), 182–195.
109. [109] Helas, S., Goettsch, C., Schoppet, M., Zeitz, U., Hempel, U., Morawietz, H., et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175 (2009), 473–478.
110. [110] Samelson, E.J., Miller, P.D., Christiansen, C., Daizadeh, N.S., Grazette, L., Anthony, M.S., et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 29 (2014), 450–457.
111. [111] Liu, M., Xiang, G., Lu, J., Xiang, L., Dong, J., Mei, W., TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling. Atherosclerosis 237 (2014), 718–724.
112. [112] Boskey, A., Bone mineral crystal size. Osteoporos Int 14 (2003), S16–S21.
113. [113] Persy, V., De Broe, M., Ketteler, M., Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels?. Kidney Int 70 (2006), 1537–1538.
114. [114] Nitta, K., Akiba, T., Suzuki, K., Uchida, K., Watanabe, R., Majima, K., et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44 (2004), 680–688.
115. [115] Toussaint, N.D., Lau, K.K., Strauss, B.J., Polkinghorne, K.R., Kerr, P.G., Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56 (2010), 57–68.
116. [116] Shao, J.S., Cheng, S.L., Charlton-Kachigian, N., Loewy, A.P., Towler, D.A., Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278 (2003), 50195–50202.
117. [117] Novaro, G.M., Tiong, I.Y., Pearce, G.L., Lauer, M.S., Sprecher, D.L., Griffin, B.P., Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001), 2205–2209.
118. [118] Iijima, K., Ito, Y., Son, B.K., Akishita, M., Ouchi, Y., Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification. J Atheroscler Thromb 21 (2014), 917–929.
119. [119] Lenglet, S., Quercioli, A., Fabre, M., Galan, K., Pelli, G., Nencioni, A., et al. Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm, 2014, 10.1155/2014/720987 ([Epub ahead of print]).
120. [120] Mori, K., Jono, S., Emoto, M., Kawagishi, T., Yasumoto, H., Konishi, T., et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 61 (2010), 86–91.
121. [121] Loomba, R.S., Arora, R., Statin therapy and aortic stenosis: a systematic review of the effects of statin therapy on aortic stenosis. Am J Ther 17 (2010), e110–e114.
122. [122] Puri, R., Nicholls, S.J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S.R., et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 65 (2015), 1273–1282.
123. [123] Mafong, D.D., Henry, R.R., Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 10 (2008), 55–60.
124. [124] Zhan, J.K., Tan, P., Wang, Y.J., Wang, Y., He, J.Y., Tang, Z.Y., et al. Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway. Cardiovasc Diabetol, 13, 2014, 153.
125. [125] Wu, S.Y., Zhang, B.H., Pan, C.S., Jiang, H.F., Pang, Y.Z., Tang, C.S., et al. Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells. Peptides 24 (2003), 1149–1156.
126. [126] Essalihi, R., Ouellette, V., Dao, H.H., McKee, M.D., Moreau, P., Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin?. J Cardiovasc Pharmacol 44 (2004), S147–S150.
127. [127] Awan, Z., Denis, M., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Awan, A., et al. Reducing vascular calcification by anti-IL-1β monoclonal antibody in a mouse model of familial hypercholesterolemia. Angiology, 2015 (pii: 0003319715583205 [Epub ahead of print]).
128. [128] Davenport, C., Mahmood, W.A., Forde, H., Ashley, D.T., Agha, A., McDermott, J., et al. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. Eur J Endocrinol 173 (2015), 53–61.
129. [129] Jamal, S.A., Vandermeer, B., Raggi, P., Mendelssohn, D.C., Chatterley, T., Dorgan, M., et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382 (2013), 1268–1277.
130. [130] Jung, S., Querfeld, U., Müller, D., Rudolph, B., Peters, H., Krämer, S., Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens 30 (2012), 2182–2191.
131. [131] Raggi, P., Chertow, G.M., Torres, P.U., Csiky, B., Naso, A., Nossuli, K., et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 (2011), 1327–1339.
132. [132] Rodriguez, M., Aguilera-Tejero, E., Mendoza, F.J., Guerrero, F., Lopez, I., Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney Int Suppl, 2008, S50–S54.
133. [133] Lau, W.L., Leaf, E.M., Hu, M.C., Takeno, M.M., Kuro-o, M., Moe, O.W., et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82 (2012), 1261–1270.
134. [134] Shea, M.K., O'Donnell, C.J., Hoffmann, U., Dallal, G.E., Dawson-Hughes, B., Ordovas, J.M., et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Neutr 89 (2009), 1799–1807.
135. [135] Spronk, H.M., Soute, B.A., Schurgers, L.J., Thijssen, H.H., De Mey, J.G., Vermeer, C., Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 40 (2003), 531–537.
136. [136] Auriemma, M., Carbone, A., Di Liberato, L., Cupaiolo, A., Caponio, C., De Simone, C., et al. Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature. Am J Clin Dermatol 12 (2011), 339–346.
137. [137] Mathews, S.J., de Las, Fuentes L., Podaralla, P., Cabellon, A., Zheng, S., Bierhals, A., et al. Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol 33 (2011), 131–138.
138. [138] Pasch, A., Schaffner, T., Huynh-Do, U., Frey, B.M., Frey, F.J., Farese, S., Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int, 74, 2008 (1444–145).